Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Sym004 Versus Futuximab or Modotuximab in Patients With mCRC

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03549338
Recruitment Status : Terminated (Study was terminated due to administrative reasons)
First Posted : June 8, 2018
Last Update Posted : April 15, 2019
Sponsor:
Information provided by (Responsible Party):
Symphogen A/S

Results Submitted - Not Posted on ClinicalTrials.gov
Results information has been submitted to ClinicalTrials.gov by the sponsor or investigator, but is not yet publicly available (or "posted") on ClinicalTrials.gov. The submitted information may not be available if it is pending Quality Control (QC) Review by the National Library of Medicine (NLM) or if issues identified during QC review are being addressed or corrected by the sponsor or investigator. NLM's limited QC review assesses for apparent errors, deficiencies, or inconsistencies. NLM staff do not verify the scientific validity or relevance of the submitted information.
Recruitment Status : Terminated
Actual Primary Completion Date : March 9, 2019
Actual Study Completion Date : March 9, 2019
Submission Cycle Results Submitted to ClinicalTrials.gov Results Returned after Quality Control Review
1 June 7, 2019
(Canceled on June 7, 2019)
June 8, 2019
June 26, 2019